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Upon exposure to the bacterial chemotactic peptide fMet-Leu-Phe, human neutrophils release lysozyme and generate
superoxide anions (20 -). The synthetic lipoamino acid N-palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-(R)-cysteine
(Pam3Cys), which is derived from the N-terminus of bacterial lipoprotein, when attached to Ser-(Lys)4 [giving Pam3Cys-
Ser-(Lys)4j, activated O2- formation and lysozyme release in human neutrophils with an effectiveness amounting to about
15 % of that of fMet-Leu-Phe. Palmitic acid, muramyl dipeptide, lipopolysaccharide and the lipopeptides Pam3Cys-Ala-
Gly, Pam3Cys-Ser-Gly, Pam3Cys-Ser, Pam3Cys-OMe and Pam3Cys-OH did not activate 02- formation. Pertussis toxin,
which ADP-ribosylates guanine-nucleotide-binding proteins (G-proteins) and functionally uncouples formyl peptide
receptors from G-proteins, prevented activation of 02.- formation by fMet-Leu-Phe and inhibited Pam3Cys-Ser-(Lys)4-
induced 02- formation by 85 %. Lipopeptide-induced exocytosis was pertussis-toxin-insensitive. O2 formation induced
by Pam3Cys-Ser-(Lys)4 and fMet-Leu-Phe was-enhanced by cytochalasin B, by a phorbol ester and by a diacylglycerol
kinase inhibitor. Addition of activators of adenylate cyclase and removal of extracellular Ca2+ inhibited O2 - formation
by fMet-Leu-Phe and Pam3Cys-Ser-(Lys)4 to different extents. Pam3Cys-Ser-(Lys)4 synergistically enhanced fMet-Leu-
Phe-induced 02O- formation and primed neutrophils to respond to the chemotactic peptide at non-stimulatory
concentrations. Our data suggest the following. (1) Pam3Cys-Ser-(Lys)4 activates neutrophils through G-proteins,
involving pertussis-toxin-sensitive and -insensitive processes. (2) The signal transduction pathways activated by fMet-Leu-
Phe and Pam3Cys-Ser-(Lys)4 are similar but not identical. (3) In inflammatory processes, bacterial lipoproteins and
chemotactic peptides may interact synergistically to activate 02.- formation, leading to enhanced bactericidal activity.
INTRODUCTION
Human neutrophils play a key role in the host defence against
bacterial infections, with bactericidal activity depending largely
on lysosomal enzyme release and on NADPH-oxidase-catalysed
superoxide (02'-) formation (Rossi, 1986; Malech & Gallin,
1987). The bacterial chemotactic peptide N-formyl-L-methionyl-
L-leucyl-L-phenylalanine (fMet-Leu-Phe) binds to formyl peptide
receptors and activates phospholipase C, catalysing poly-
phosphoinositide degradation to diacylglycerol and inositol
phosphates (Rossi, 1986). Diacylglycerol activates protein kinase
C, and inositol trisphosphate mobilizes intracellular Ca2l. Formyl
peptide receptors interact with guanine-nucleotide-binding pro-
teins (G-proteins), whose ADP-ribosylation by pertussis toxin
prevents cell activation. The mechanism by which chemotactic
peptides activate NADPH oxidase may involve protein kinase C,
Ca2+ mobilization and direct stimulation by G-proteins (Rossi,
1986; Seifert et al., 1986; Seifert & Schultz, 1987a,b).
The outer cell wall of Gram-negative bacteria contains lipo-
polysaccharide and lipoprotein (Braun, 1975; Guthrie et al.,
1984; Forehand et al., 1989). Lipoproteins and synthetic ana-
logues derived from the N-terminus of lipoproteins are potent
activators of macrophages and lymphocytes (Melchers et al.,
1975; Resch & Bessler, 1981; Bessler et al., 1985; Hoffmann
et al., 1988; Hauschildt et al., 1989). Lipopolysaccharide primes
neutrophils for enhanced O2.- formation (Guthrie et al., 1984;
Forehand et al., 1989), but the effects of lipoproteins on 02.-
formation have not yet been studied. The synthetic lipopeptide
N-palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-(R)-
cysteinyl-(S)-seryl-(S)-lysyl-(S)-lysyl-(S)-lysyl-(S)-lysine
[Pam3Cys-Ser-(Lys)4] contains two ester-bound and one amide-
bound palmitoyl residues attached to S-glyceryl-cysteine (Fig. 1).
In the murine macrophage cell line P388D1, but not in murine
B-lymphocytes or bone-marrow-derived macrophages, synthetic
lipopeptides induce polyphosphoinositide degradation and trans-
location of protein kinase C (Hauschildt et al., 1988; Steffens
et al., 1989). Recently it has been shown that synthetic viral
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Fig. 1. Structural formula of Pam3Cys-Ser-(Lys)4
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peptides covalently linked to lipopeptides, such as the influenza
virus itself, induce high-affinity cytotoxic T-lymphocytes in vivo
(Deres et al., 1989). We report here that PaM3Cys-Ser-(Lys)4
activates 02.- formation and exocytosis in human neutrophils
through pertussis-toxin-sensitive and -insensitive signal trans-
duction pathways.
MATERIALS AND METHODS
Materials
The lipopeptides Pam3Cys-Ser (Prass et al., 1987), Pam3Cys-
Ser-Gly, Pam3Cys-Ala-Gly and Pam3Cys-Ser-(Lys)4 (Reiter-
mann et al., 1989), and the lipoamino acid Pam3Cys-OH
(Wiesmuller et al., 1983) and its methyl ester Pam3Cys-OMe
(Jung et al., 1983) were prepared by chemical synthesis and were
unequivocally characterized by various analytical and spectro-
scopic methods such as mass spectroscopy, 13C n.m.r. spectro-
scopy and chiral-phase amino acid analysis. None of the lipo-
peptides studied induced the release of lactate dehydrogenase,
and staining of human neutrophils with Trypan Blue (results not
shown) suggesting that lipopeptides are not cytotoxic in the
concentrations supplied. Pertussis toxin was a gift from Dr. M.
Yajima (Kyoto, Japan). Staurosporine was from Fluka (Buchs,
Switzerland), and 6-[2{4-[(4-fluorophenyl)phenylmethylene]- 1-
piperidinyl}ethyl]-7-methyl-5H-thiazolo-[3,2-alpyrimidin-5-one
(R 59 022) was from Janssen (Olen, Belgium). N-Ethylmaleimide
(NEM), lipopolysaccharide from Escherichia coli (serotype
055: B5), muramyl dipeptide (N-acetylmuramyl-L-alanyl-D-
isoglutamine) and lyophilized Micrococcus Iysodeikticus were
obtained from Sigma Chemie (Taufkirchen, Germany).
Recombinant human tumour necrosis factor-a (TNFa) was from
Boehringer Mannheim (Mannheim, Germany). Sources of other
materials have been described elsewhere (Seifert et al., 1986,
1989a,b,c; Seifert & Schultz, 1987a,b; Seifert & Schachtele, 1988;
Burde et al., 1989).
Isolation of neutrophils
Human neutrophils were prepared as described previously in
detail (Markert et al., 1984; Seifert et al., 1989b). Briefly, blood
was obtained by venous puncture from healthy volunteers.
Neutrophils were isolated by Dextran sedimentation and centri-
fugation through Ficoll-Hypaque. Cell preparations consisted of
more than 98 % viable neutrophils as judged by Trypan Blue dye
exclusion.
Assay for 02- generation
02 - formation was monitored at 550 nm by continuous
measurement of ferricytochrome c reduction inhibitable by
superoxide dismutase, using an Uvikon 810 dual-beam spectro-
photometer (Kontron, Eching, Germany) (Markert et al., 1984;
Seifert et al., 1989b). Reaction mixtures (0.5 ml) contained
100 ,tM-ferricytochrome c and a buffer consisting of 138 mM-
NaCl, 6 mM-KCI, I mM-MgCl2, 1 mM-CaCI2, 5.5 mM-glucose and
20 mM-Hepes/NaOH, pH 7.4. Cells (1.0 x 106 neutrophils) were
preincubated for 3 min in the absence or presence of various
additives at 37 'C. 02- formation was initiated by the addition of
the stimuli. Reference cuvettes contained all of the components
listed above, plus superoxide dismutase (50,ug).
Assay for lysozyme and f/-glucuronidase release
Exocytosis was assessed as described (Absolom, 1986; Seifert
et al., 1989c; Burde et al., 1989). Briefly, neutrophils (5 x 106
cells) were incubated in buffer (0.5 ml) for 5 min in the presence
of cytochalasin B (CBj (1 ,ug/ml). At 10 min after addition of
stimuli, the tubes were cooled to 0 'C and were centrifuged for
10 min at 250 g. Determination of the activities of lysozyme, /J-
glucuronidase and lactate dehydrogenase in the supernatant
fluids of reaction mixtures and of cell lysates was performed as
described (Absolom, 1986; Seifert et al., 1989c; Burde et al.,
1989). The release of lactate deydrogenase generally amounted to
< 5 % of the cellular content (results not shown).
Statistics
Data shown in Tables 1-6 are the means+ S.D. of five to seven
experiments. The significance of the effects was assessed using the
Wilcoxon test.
RESULTS
Activation of 02- formation by Pam3Cys-Ser-(Lys)4 in human
neutrophils: kinetics and concentration-dependency
fMet-Leu-Phe at a submaximally stimulatory concentration
(30 nM) induced 02- formation with a lagtime of < 10 s, ceasing
after 4-5 min (Fig. 2, trace 3). In contrast, Pam3Cys-Ser-(Lys)4 at
submaximally and maximally stimulatory concentrations
(30 #sg/ml and 100 ,ug/ml respectively) induced 02- formation
with a lagtime of > 1 min, not ceasing until 8-9 min (Fig. 2,
traces 1 and 2). Pam3Cys-Ser-(Lys)4 at a maximally stimulatory
concentration was a less effective activator of02- formation than
the chemotactic peptide at 30 nm (compare traces 2 and 3). The
addition of Pam3Cys-Ser-(Lys)4 (30 ,g/ml) to neutrophils 3 min
before or together with fMet-Leu-Phe resulted in synergistic
activation ofNADPH oxidase with respect to the maximum rate
of 02.- formation and the absolute amount of 02-- generated
(trace 6). 02-- formation synergistically induced by the chemo-
tactic peptide and the lipopeptide was characterized by a period
lasting about 2 min with a high rate of 02.- formation and was
followed by a period lasting about 9 min during which 02'
formation declined slowly. The lipopeptide re-initiated 02--
formation when added to neutrophils after the fMet-Leu-Phe-
induced 02.- formation had ceased (Fig. 2, traces 4 and 5).
However, the extent of NADPH oxidase activation induced by
the lipopeptide in fMet-Leu-Phe-stimulated neutrophils was not
greater than in unstimulated cells (compare trace 1 with trace 4
and trace 2 with trace 5).
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Fig. 2. Kinetics of 02-- formation in human neutrophils
Trace 1, addition of Pam3Cys-Ser-(Lys)4 (30 jug/ml) at time B; trace
2, addition of Pam3Cys-Ser-(Lys)4 (100 /sg/ml) at time B; trace 3,
addition of fMet-Leu-Phe (30 nM) at time B; trace 4, addition of
Pam3Cys-Ser-(Lys)4 (30 jug/ml) at time C; trace 5, addition of
Pam3Cys-Ser-(Lys)4 (100,ug/ml) at time C; trace 6, addition of
fMet-Leu-Phe (30 nM) at time B plus Pam3Cys-Ser-(Lys)4 (30 ,ug/ml)
at time A or B. Experiments were carried out in the absence of CB.
Superimposed original registrations from one single experiment are
shown. Similar results were obtained in six identical experiments.
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Fig. 3. Concentration-response curve ofPam3Cys-Ser-(Lys)4-induced 02'-
formation in human neutrophils
Experiments were carried out in the presence of CB (1 #sg/ml). 0,
Maximum rate of02,- formation; *, total amount of02'- generated.
Data shown are the means + S.D. of three experiments.
Fig. 3 shows the concentration-response curve for activation
of NADPH oxidase by Pam3Cys-Ser-(Lys)4. The experiments
were carried out in the presence of CB, which potentiates
receptor-mediated 02-- formation by inhibiting sequestration of
plasma membrane receptors (Jesaitis et al., 1986). The lipopeptide
activated 02;- formation in a concentration-dependent manner
with respect to the maximum rate and the absolute amount of02.-
generated. The effect of Pam3Cys-Ser-(Lys)4 was half-maximal at
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60-70 ,ug/ml and reached a plateau at 100 ,ug/ml. In contrast,
muramyl dipeptide and the lipopeptides Pam3Cys-OH, Pam3Cys-
OMe, Pam3Cys-Ser, Pam3Cys-Ser-Gly and Pam3Cys-Ala-Gly at
1-100 ,ug/ml did not activate 02-- formation in the absence or
presence of CB (results not shown). Palmitic acid and lipopoly-
saccharide at 1-100 ,sg/ml did not activate 02- formation in
suspended neutrophils (results not shown).
Activation of 02- formation by Pam3Cys-Ser-(Lys)4: role of
G-proteins
In order to elucidate the role of G-proteins in the activation of
02- formation by Pam3Cys-Ser-(Lys)4, neutrophils were treated
with pertussis toxin. Pertussis toxin inhibited 02- formation
induced by fMet-Leu-Phe and Pam3Cys-Ser-(Lys)4 but not by
phorbol 12-myristate 13-acetate (PMA), which circumvents re-
ceptor stimulation by activating protein kinase C directly (Fig.
4). The inhibitory effect of pertussis toxin on fMet-Leu-Phe- and
lipopeptide-induced 02-- formation was half-maximal at
5-10 ng/ml and maximal at 1 /g/ml. Pertussis toxin completely
abolished the stimulatory effect of fMet-Leu-Phe, whereas the
effect of Pam3Cys-Ser-(Lys)4 was inhibited by up to 85 %. The
effect of pertussis toxin on 02-- formation was time-dependent.
Half-maximal inhibition of fMet-Leu-Phe- and lipopeptide-
induced 02.- formation was observed after 60-75 min of toxin
treatment. Inhibition of chemotactic-peptide-induced 02- form-
ation was complete after an incubation time of 3 h. Again,
pertussis toxin did not completely abolish the stimulatory effect
of Pam3Cys-Ser-(Lys)4 on 02' formation.
Synergistic activation of 02-- formation by fMet-Leu-Phe and
Pam3Cys-Ser-(Lys)4
The synergistic effects of fMet-Leu-Phe and Pam3Cys-Ser-
(Lys)4 were studied in detail. The experiments shown in Fig. 5
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Fig. 4. Inhibition of 02.- formation by pertussis toxin in human neutrophils
Neutrophils were suspended at a concentration of 107 cells/ml in the assay buffer for determination of02- formation not supplemented with CaCl2
and were incubated with pertussis toxin or its vehicle. Following toxin treatment, cells were transferred into cuvettes and assayed for 02-- formation.
(a) Concentration-dependence. Neutrophils were incubated for 3 h in the presence of pertussis toxin at the indicated concentrations. (b) Time
dependence. Cells were incubated in the presence of pertussis toxin (I /sg/ml) for the indicated periods of time. The concentrations of stimuli were
as follows: A, PMA (100 ng/ml); *, 1 4aM-fMet-Leu-Phe plus CB (1 jg/ml); 0, Pam3Cys-Ser-(Lys)4 (100 jug/ml) plus CB (1 ,ug/ml). Data shown
are the means + S.D. of six experiments. The inhibitory effect of pertussis toxin on Pam3Cys-Ser-(Lys)4-induced °2- formation was significant
(P < 0.05 or P < 0.01) at toxin concentrations of 1-1000 ng/ml and incubation times of 1-3 h.
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Fig. 5. Synergistic activation of 02- formation by Pam3Cys-Ser-(Lys)4
and fMet-Leu-Phe in human neutrophils
The effects of fMet-Leu-Phe at various concentrations were studied
in the presence of Pam3Cys-Ser-(Lys)4 at three fixed concentrations.
Experiments were carried out in the absence of CB. 0, Solvent
(control); *, Pam3Cys-Ser-(Lys)4 (10l g/ml); A, Pam3Cys-Ser-
(Lys)4 (30 zg/ml); V, Pam3Cys-Ser-(Lys)4 (100/Og/ml). Pam3Cys-
Ser-(Lys)4 plus fMet-Leu-Phe were added simultaneously to reaction
mixtures. Data shown are the means of assay duplicates, which
varied by less than 50%. Similar results were obtained in three
experiments.
were carried out in the absence of CB. fMet-Leu-Phe activated
02- formation with an EC50 (concn. causing 500% of maximal
stimulation) of 40 nm and maximum stimulation at 300 nm.
Pam3Cys-Ser-(Lys)4 at a non-stimulatory concentration
(10 ,ug/ml) enhanced the 02- formation induced by a fMet-Leu-
Phe concentration above 30 nm by up to 30 %. The lipopeptide
at a submaximally stimulatory concentration (30 ,ug/ml) primed
neutrophils to respond to the chemotactic peptide at a non-
stimulatory concentration (10 nM) and enhanced 02- formation
induced by fMet-Leu-Phe at submaximally and maximally stimu-
latory concentrations by up to 45 % without significantly
lowering the EC50 for the formyl peptide. Pam3Cys-Ser-(Lys)4 at
a maximally effective concentration (100 ,ug/ml) primed neutro-
phils for a fMet-Leu-Phe concentration as low as 1 nm and
enhanced the effect of fMet-Leu-Phe at submaximally and
maximally stimulatory concentrations by up to 2-fold.
Table 1. Effects of various lipopeptides on fMet-Leu-Phe-induced 02;-
formation in human neutrophils
The effects of various lipopeptides on O2;- formation induced by
fMet-Leu-Phe (lsM) were assessed. Lipopeptides at 100 ,g/ml or
solvent (control) were added to reaction mixtures simultaneously
with the chemotactic peptide. Experiments were carried out in the
absence of CB. Significant differences from control are indicated by
*P <0.05; **P <0.01.
02s- formation
Lipopeptide (nmol/min per 106 cells)
None 5.2+0.8
Pam3Cys-Ser-(Lys)4 12.2+ 1.4**
Pam3Cys-Ala-Gly 3.8 +0.9
Pam3Cys-Ser-Gly 4.1 +0.7
Pam3Cys-Ser 3.5 + 0.6*
Pam3Cys-OMe 3.6 + 0.4*
Pam3Cys-OH 1.2+0.3**
The interaction of fMet-Leu-Phe and Pam3Cys-Ser-(Lys)4 was
markedly affected by CB (results not shown). In the presence of
CB, neutrophils generated 02- at similar rates upon exposure to
fMet-Leu-Phe at 3 nM and to Pam3Cys-Ser-(Lys)4 at 100 ,ag/ml.
The lipopeptide and the chemotactic peptide at these concen-
trations activated 02 formation additively. However, with fMet-
Leu-Phe at a maximally stimulatory concentration (1 gM), no
synergism with Pam3Cys-Ser-(Lys)4 was apparent.
Table I summarizes the effects of various lipopeptides at
100ltg/ml on fMet-Leu-Phe-induced 02.- formation in the ab-
sence of CB. In contrast with Pam3Cys-Ser-(Lys)4, the lipo-
tripeptides Pam3Cys-Ala-Gly and Pam3Cys-Ser-Gly did not
significantly affect 02;- formation, whereas Pam3Cys-Ser and
Pam3Cys-OMe inhibited 02;- formation by up to 350% and
Pam3Cys-OH inhibited 02.- formation by more than 75 %.
PMA, UTP, platelet-activating factor (PAF) and TNFa prime
neutrophils for enhanced 02-- formation upon exposure to fMet-
Leu-Phe (Dewald & Baggiolini, 1985; Tyagi et al., 1988; Seifert
et al., 1989a,b,c; Yuo et al., 1989). Therefore we compared the
interaction of these priming agents with fMet-Leu-Phe and
Pam3Cys-Ser-(Lys)4 (Table 2). Neither UTP nor TNFa per se
induced 02-- formation. PMA at 1 ng/ml induced °2 formation
at a low rate, and PAF (1 /sM) activated 02' formation to an
extent amounting to 300% of that induced by fMet-Leu-Phe
(1 ,sM). PMA, TNFa, UTP and PAF interacted synergistically
with fMet-Leu-Phe to activate 02- formation. In contrast, only
PMA but not TNFa, UTP or PAF interacted synergistically with
Pam3Cys-Ser-(Lys)4 to activate NADPH oxidase.
Table 2. Priming of human neutrophils for enhanced 02- formation with PMA, TNFcc, UTP and PAF
The effects of PMA, TNFa, UTP and PAF on 02-- formnation induced by fMet-Leu-Phe (1 #M), Pam3Cys-Ser-(Lys)4 (100 /tg/ml) or solvent
(control) were studied. PAF was added to reaction mixtures together with Met-Leu-Phe or Pam3Cys-Ser-(Lys)4. PMA and UTP were added to
reaction mixtures 3 min before addition of stimuli, and TNFa was added 15 min before addition of stimuli. Experiments were carried out in the
absence of CB. Significant differences from control (no addition) are indicated by *P < 0.05, **P < 0.01.
02-- formation (nmol/min per 106 cells)
Addition Control fMet-Leu-Phe Pam3Cys-Ser-(Lys)4
None
PMA (1 ng/ml)
TNFa (6 nM)
UTP (100 /uM)
PAF (1 M)
0 4.9+0.4
0.3 +0.1 7.7+0.8**
0 8.8+0.5**
O 9.2 + 0.9**
1.5 +0.2 11.3 + 1.0**
1.3 +0.4
2.2 + 0.3*
1.3 + 0.5
1.2+0.4
0.9 +0.2
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Table 3. Effects of various drugs on 02-- formation in human neutrophils induced by fMet-Leu-Phe and Pam3Cys-Ser-(Lys)4
The effects of various drugs on 02-- formation induced by fMet-Leu-Phe (1 1M) and Pam3Cys-Ser-(Lys)4 (100 ug/ml) were studied. Drugs or
solvent (control) were added to reaction mixtures 3 min before addition of stimuli. Significant differences from control values (no addition) are
indicated by *P < 0.05; **P < 0.01.
02- formation (nmol/min per 106 cells)
Addition fMet-Leu-Phe Pam3Cys-Ser-(Lys)4
None
Staurosporine (1 uM)
NEM (1 mM)
EDTA (1 mM), no Ca2' added
CB (1 /ug/ml)
R 59 022 (10/M)
4.8 +0.4
O**
O**
0.7 + 0.3**
9.9+ 1.2**
10.4+ 1.2**
0.6+0.2
O**
O**
0.4 + 0.2*
1.3 + 0.3**
1.4+0.2**
Modulation of 02 formation by various drugs
The effects of various drugs on chemotactic peptide- and
lipopeptide-induced 02-- formation were compared (Table 3).
Staurosporine, a potent inhibitor of protein kinases (Schachtele
et al., 1988; Ruegg & Burgess, 1989), and the thiol reagent NEM
abolished 02-- formation induced by both Pam3Cys-Ser-(Lys)4
and fMet-Leu-Phe. The removal of extracellular Ca2+ decreased
fMet-Leu-Phe-induced 02-- formation by more than 800%,
whereas the effect of Pam3Cys-Ser-(Lys)4 was diminished only by
about 30 %. CB and R 59 022, the inhibitor of diacylglycerol
kinase (de Chaffoy de Courcelles et al., 1985), enhanced chemo-
tactic peptide- and lipopeptide-induced 02 formation by up to
2.5-fold.
02-- formation induced by various receptor agonists is differen-
tially inhibited by the activators of adenylate cyclase, prosta-
glandin E1 (PGE1), isoprenaline, histamine and cholera toxin
(Seifert et al., 1989a; Burde et al., 1989). PGE1, isoprenaline and
histamine inhibited fMet-Leu-Phe-induced 02- formation by up
to 55 %, whereas the effect of Pam3Cys-Ser-(Lys)4 was inhibited
by up to 850% (Table 4). In agreement with a recent report,
cholera toxin did not significantly inhibit fMet-Leu-Phe-induced
02-- formation (Gabler et al., 1989). In contrast, cholera toxin
inhibited the effect of Pam3Cys-Ser-(Lys)4 by about 7000.
Activation of exocytosis by Pam3Cys-Ser-(Lys)4
The role of lipopeptides in the regulation of exocytosis was
Table 4. Inhibition by activators of adenylate cyclase of 02M- formation induced by fMet-Leu-Phe and Pam3Cys-Ser-(Lys)4 in human neutrophils
The effects of various activators of adenylate cyclase on 02- formation induced by fMet-Leu-Phe (1 #M) or Pam3Cys-Ser-(Lys)4 (100 /tg/ml) plus
CB (1 ,ug/ml) were studied. PGE1, isoprenaline, histamine or solvent (control) were added to reaction mixtures 3 min before addition of stimuli.
Cells were treated with cholera toxin or its vehicle for 3 h according to the procedure described in the legend to Fig. 4. Significant differences from
control values (no additions) are indicated by *P < 0.01.
02- generation (nmol/min per 106 cells)
Addition fMet-Leu-Phev Pam3Cys-Ser-(Lys)4
None
PGE1 (1o UM)
Isoprenaline (1 M)
Histamine (1 mM)
Cholera toxin (1 ,ug/ml)
8.9+0.5
4.1 +0.6*
5.6+ 1.3*
5.4 + 0.9*
7.7+0.9
1.2+0.3
0.2+0.1*
0.4+ 0.2*
0.2+0.1*
0.4+0.2*
Table 5. Synergistic activation of lysozyme release in human neutrophils by fMet-Leu-Phe and Pam3Cys-Ser-(Lys)4
The effects of fMet-Leu-Phe and of Pam3Cys-Ser-(LY6)4 and combination of both stimuli on lysozyme release in human neutrophils were studied.
Neutrophils were treated with CB (1 #esg/ml) for 5 min before addition of stimuli. Assays were conducted for a period of 10 min. Comparison of
the effectiveness of fMet-Leu-Phe or Pam3Cys-Ser-(Lys)4 versus solvent (control): *P < 0.01. Comparison of fMet-Leu-Phe alone versus fMet-
Leu-Phe plus Pam3Cys-Ser-(Lys)4: tP < 0.05.
Lysozyme release
(% of cellular content)Stimulus
None
fMet-Leu-Phe (30 nM)
fMet-Leu-Phe (1 /SM)
Pam3Cys-Ser-(Lys)4 (100 jug/ml)
fMet-Leu-Phe (30 nM) + Pam,,Cys--Ser-(Lys)4 (100 ,ug/ml)
fMet-Leu-Phe (1 /M)+ Pam3Cys-Ser-(Lys)4 (100 Sg/ml)
4.3 i1.5
12.8±2.1*
34.0+ 3.9*
10.3 + 2.7*
19.0+3.Ot
38.6± 5.2
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Table 6. Effect of pertussis toxin on exocytosis in human neutrophils induced by fMet-Leu-Phe and Pam3Cys-Ser-(Lys)4
Neutrophils were treated with pertussis toxin (PTX) at 1 ,ug/ml or its vehicle under the conditions described in the legend to Fig. 4. Cells were
preincubated with CB (1 jug/ml) for 3 min before the addition of stimuli or solvent (control). The concentrations of stimuli were as follows: fMet-
Leu-Phe, 1 /M; Pam3Cys-Ser-(Lys)4, lOO,10g/ml; A23187, 10 /SM. Effectiveness of stimuli to induce exocytosis in control cells: *P < 0.01.
Effectiveness of PTX to inhibit exocytosis versus control cells: tP < 0.01.
,6-Glucuronidase release Lysozyme release
(% of cellular content) (% of cellular content)
Stimulus Treatment ... None PTX None PTX
None
fMet-Leu-Phe
Pam3Cys-Ser-(Lys)4
A23187
5.6+0.6
30.7+2.1*
5.9+0.4
44.3+2.8*
6.2+0.6
5.1 +0.5t
4.9+1.6
43.0+ 5.6
4.1 +0.2
32.1 + 1.9*
11.1+2.8*
41.0 + 5.4*
3.8 + 1.8
10.1 + 1.0t
12.0+2.3
38.0 + 5.5
studied (Tables 5 and 6). Lysozyme is localized in the azurophilic
and specific granules, and fl-glucuronidase is present only in the
azurophilic granules (Absolom, 1986). Pam3Cys-Ser-(Lys)4 at
100 jug/ml induced lysozyme release to a similar extent as did the
chemotactic peptide at 30 nm. In addition, the lipopeptide and
fMet-Leu-Phe (30 nM) induced lysozyme release additively. How-
ever, fMet-Leu-Phe at 1 ,UM and Pam3Cys-Ser-(Lys)4 showed no
additive effect on lysozyme release. Pam3Cys-Ser-(Lys)4 did not
induce f,-glucuronidase release, suggesting that the lipopeptide
induced only exocytosis of specific granules.
Human neutrophils were treated with pertussis toxin (I ,ug/ml)
for 3 h (see Fig. 4). Pertussis toxin completely inhibited fMet-
Leu-Phe-induced ,-glucuronidase release and did not inhibit
exocytosis induced by the Ca2+ ionophore, A23 187, which
circumvents receptor stimulation by increasing the intracellular
Ca2+ concentration directly. In addition, pertussis toxin inhibited
fMet-Leu-Phe-induced lysozyme release by 75 %, whereas
Pam3Cys-Ser-(Lys)4-induced exocytosis was not affected by the
toxin treatment.
DISCUSSION
Similarities and dissimilarities between lipopeptides and other
activators of neutrophils: role of plasma membrane receptors
and G-proteins
Lipoproteins are major constituents of bacterial cell walls
(Braun, 1975). We report here on the activation of02- formation
and lysozyme release in human neutrophils by the synthetic
lipohexapeptide Pam3Cys-Ser-(Lys)4. The identification of a
35 kDa lipopeptide-binding protein in murine B-lymphocytes by
Biesert et al. (1987) raises the possibility that activation of
NADPH oxidase by Pam3Cys-Ser-(Lys)4 is mediated through
specific binding proteins as well. In order to answer this question
we compared activation of 02- formation by fMet-Leu-Phe and
Pam3Cys-Ser-(Lys)4. Activation of NADPH oxidase by chemo-
tactic peptides and lipopeptides has several characteristics in
common, i.e. the ceasing of 02.- formation after some minutes,
the (at least partial) dependency on extracellular Ca2 , sensitivity
to NEM, pertussis toxin, activators of adenylate cyclase and
staurosporine, and potentiation by PMA, CB and R 59022
(Figs. 2 and 4; Tables 2-4). In addition, activation of 02--
formation by lipopeptides shows specificity for the amino acid
chain (see Table 2). These data suggest that activation ofNADPH
oxidase by Pam3Cys-Ser-(Lys)4 is a receptor-mediated process
which involves activation of pertussis-toxin-sensitive G-proteins.
How can the partial pertussis-toxin-sensitivity of lipopeptide-
induced 02.- formation -and pertussis-toxin-insensitivity of
lipopeptide-induced exocytosis (Fig. 4; Table 6) be explained? It
is well known that activation of human myeloid cells by various
classes of receptor agonists, e.g. IgG, purine nucleotides and
cytokines, shows partial pertussis-toxin-insensitivity (Blackburn
& Heck, 1988; Dubyak et al., 1988; Richter et al., 1989; Seifert
et al., 1989a). These data suggest that receptors for these
intercellular signal molecules interact, at least in part, with ADP-
ribosylated G-proteins, and/or that pertussis-toxin-insensitive
G-proteins are involved in the signal transduction pathway,
including GTP-binding proteins with molecular masses of
approx. 20 kDa (Bokoch & Parkos, 1988). In addition, there is
recent evidence that different types of receptors interact specific-
ally with pertussis-toxin-sensitive or -insensitive G-proteins,
ultimately leading to activation of the same effector system
(Ashkenazi et al., 1989). Furthermore, McLeish et al. (1989)
reported that formyl peptide and leukotriene B4 receptors in
human myeloid cells interact differently with G-proteins. Another
explanation for the partial pertussis-toxin-insensitivity of the
effects of Pam3Cys-Ser-(Lys)4 is outlined below.
There are some dissimilarities between O2- formation induced
by chemotactic peptides and by Pam3Cys-Ser-(Lys)4, i.e. the
differential sensitivity to pertussis toxin and cyclic AMP-
increasing agents and dependency on extracellular Ca2+ (Fig. 4;
Tables 3 and 4). In addition, TNFa, UTP and PAF prime
neutrophils for fMet-Leu-Phe but not for Pam3Cys-Ser-(Lys)4
(see Table 2). Furthermore, the onset of Pam3Cys-Ser-(Lys)4-
induced 02- formation is delayed, suggesting that the lipopeptide
reaches its target of action more slowly than does fMet-Leu-Phe
(see Fig. 2) (Seifert et al., 1989b). Finally, the kinetics of
synergistic activation of 02.- formation by fMet-Leu-Phe and
UTP or PAF or Pam3Cys-Ser-(Lys)4 are quite different (Fig. 2)
(Seifert et al., 1989b,c), and UTP and PAF, but not Pam3Cys-
Ser-(Lys)4, interacted synergistically with fMet-Leu-Phe when
added to neutrophils after the chemotactic-peptide-induced 02.-
formation had ceased (Fig. 1; Dewald & Baggiolini, 1985; Seifert
et al., 1989c). These data suggest that activation of NADPH
oxidase by lipopeptides involves mechanisms additional to those
by which fMet-Leu-Phe, UTP and PAF activate this effector
system. This assumption is also supported by our finding that
Pam3Cys-Ser-(Lys)4, unlike fMet-Leu-Phe, does not induce ,-
glucuronidase release (see Table 6).
There are some functional dissimilarities between lipopoly-
saccharide and lipopeptides with respect to NADPH oxidase
regulation. First, lipopolysaccharide per se does not activate O2'
formation in suspended neutrophils but only in adherent cells
(Dahinden et al., 1983), whereas Pam3Cys-Ser-(Lys)4 is effective
in suspended neutrophils (see Fig. 2). Lipopolysaccharide primes
neutrophils for enhanced O2- formation in a pertussis-toxin-in-
sensitive manner (Forehand et al., 1989). By contrast, the effects
of lipopeptides on O2 --formation are, at least in part, pertussis-
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toxin-sensitive (Fig. 4). In addition, the priming effect of lipopoly-
saccharide on 02;- formation becomes evident only with in-
cubation times longer than 30 min, whereas the priming effect of
Pam3Cys-Ser-(Lys)4 is evident immediately (Fig. 2). These data
indicate that lipopolysaccharide and lipopeptides are functionally
non-equivalent and play different roles in the regulation of
NADPH oxidase.
Structure-activity studies with lipopeptides
The analysis of the structure-activity relationship for
lipopeptide-induced activation of 02-- formation provides im-
portant information concerning the mode of action of these
compounds (Table 1). Among a variety of lipopeptides studied,
Pam3Cys-Ser-(Lys)4 is the only one with stimulatory effects on
neutrophils. In contrast, Pam3Cys-Ala-Gly and Pam3Cys-Ser-
Gly are inactive and Pam3Cys-Ser, Pam3Cys-OMe and Pam3Cys-
OH are inhibitory. The difference between Pam3Cys-Ser-(Lys)4
and the other lipopeptides is that the former possesses four
positively charged amino groups in the lysyl residues of the
hexapeptide chain (see Fig. 1). Apparently these positive charges,
which facilitate the interaction with negatively charged domains
of phospholipids and proteins, are important for the stimulatory
action ofPam3Cys-Ser-(Lys)4. In murine lymphocytes, Pam3Cys-
Ser-(Lys)4, Pam3Cys-Ser and Pam3Cys-Ala-Gly are similarly
effective cell activators, and Pam3Cys-OH and Pam3Cys-OMe
are only weakly active (Bessler et al., 1985; Reitermann et al.,
1989). These data suggest that the interaction of lipopeptides
with plasma membranes is cell-type-specific.
There are some structural and functional similarities between
Pam3Cys-Ser-(Lys)4 and the tetradecapeptide mastoparan, which
is found in wasp venom. Both Pam3Cys-Ser-(Lys)4 and masto-
paran are amphiphilic and bear positive charges (Fig. 1)
(Higashijima et al., 1988). Thus both molecules may cross the
plasma membrane to reach intracellular targets of action. In
addition, mastoparan mimicks certain aspects of agonist-induced
cell activation (Okano et al., 1985; Wilson, 1989; Wojcikiewicz
& Nahorski, 1989; Yokokawa et al., 1989) as does Pam3Cys-Ser-
(Lys)4. Furthermore, Higashijima et al. (1988) have shown that
mastoparan directly interacts with G-proteins, possibly by mim-
icking the effects of basic loops of plasma membrane receptors.
Finally, studies with intact cells and purified G-proteins showed
that mastoparan-induced activation of G-proteins is partially
pertussis-toxin-resistant (Higashijima et al., 1988; Yokokawa
et al., 1989). By analogy, the effects of Pam3Cys-Ser-(Lys)4 on O2-
formation are also partially resistant to inhibition by pertussis
toxin (Fig. 4), and its effects on lysozyme release are not inhibited
by the toxin at all (Table 6).
Lipopeptides as potentiators of neutrophil activation
Anotho r aspect of neutrophil activation by Pam3Cys-Ser-
(Lys)4 is its synergism with chemotactic peptides (Figs. 2 and 5;
Tables 1 and 5). The synergism between the two classes of stimuli
on 02- formation is still evident in the presence of the agonists at
maximally stimulatory concentrations, suggesting that they ac-
tivate neutrophils by different mechanisms. This assumption is
supported by the differential sensitivity of lipopeptide- and
chemotactic-peptide-induced 02- formation to various inhibitory
drugs and by the different kinetics of O2'- formation (see Figs. 2
and 4; Tables 3 and 4). Pam3Cys-Ser-(Lys)4 primes neutrophils
for fMet-Leu-Phe at non-stimulatory concentrations but does
not substantially shift the concentration-response function to
chemotactic peptide-induced 02- formation to the left, suggesting
that it does not alter the affinity state of formyl peptide receptors.
However, GB blunts synergistic interaction of Pam3Cys-Ser-
(Lys)4 with fMet-Leu-Phe, indicating that the lipopeptide and
CB act, at least in part, by a mechanism they have in common,
i.e. by preventing receptor sequestration and by expressing new
plasma membrane formyl peptide receptors (Jesaitis et al., 1986).
Additional mechanisms by which lipopeptides potentiate
chemotactic-peptide-induced activation of NADPH oxidase may
involve synergistic activation of stimulatory G-proteins, amplific-
ation of the activation of effector systems and generation of
intracellular signal molecules, and translocation of cytosolic
components of NADPH oxidase to the plasma membrane.
Physiological role of lipopeptides as activators of human
neutrophils
Finally, what may be the physiological relevance of neutrophil
activation by lipoproteins? As lipoproteins are present in Gram-
negative bacteria, they would be expected to serve as intercellular
signal molecules for neutrophils in inflammatory processes, as is
the case for chemotactic peptides (Braun, 1975; Rossi, 1986;
Malech & Gallin, 1987). A major obstacle to the proper
interpretation of experiments with purified lipoprotein is its
potential contamination with small amounts of other bacterial
products, e.g. lipopolysaccharide, and its poor solubility in
aqueous media (Bessler et al., 1985). These problems are over-
come by the use of chemically synthesized lipopeptides containing
the pure biologically active N-terminal moiety of native lipo-
proteins. Pam3Cys-Ser-(Lys)4 per se is a much less effective
activator of 02-- formation and exocytosis than fMet-Leu-Phe,
but potentiates the effects of chemotactic peptides (Figs. 2 and 5;
Table 5). These data suggest that lipopeptides function pre-
dominantly as priming agents, as do purine and pyrimidine
nucleotides, PAF and TNFa (Table 3). Apparently, all of these
potentiators of neutrophil activation are functionally non-
equivalent. Of potential physiological relevance is the finding
that Pam3Cys-Ser-(Lys)4 induces the release of lysozyme which
degrades murein, to which lipoproteins are covalently attached
(Braun, 1975; Absolom, 1986) (Tables 5 and 6). Lipoprotein-
induced lysozyme release from neutrophils would thus provide a
feed-forward signal for enhanced bactericidal activity, a process
which is accompanied by an increased release of lipoprotein from
bacteria.
It should be noted that the lipopeptides used in our present
study, in particular Pam3Cys-Ser-(Lys)4, are not secretory pro-
ducts of Gram-negative bacteria. It is likely that lipopeptides
bearing positively charged amino acids are released from native
lipoprotein during its proteolytic degradation, but this process
has not yet been studied (Braun, 1975). The activation in vivo of
2-- formation bychemotactic peptides is modulated substantially
by various factors such as adherence and cytokines (Dahinden
et al., 1983; Nathan, 1987). In what way these factors may affect
lipopeptide-induced 2-- formation in vivo is not known. Thus at
present it is difficult to finally assess the physiological relevance
of neutrophil activation by lipopeptides.
In summary, we provide evidence that the synthetic lipopeptide
Pam3Cys-Ser-(Lys)4 is a neutrophil activator which possesses
properties both similar and dissimilar to other classes of neutro-
phil activators, suggesting that it activates neutrophils through a
unique transmembrane signalling process. In addition, our data
suggest that Pam3Cys-Ser-(Lys)4 may be a useful experimental
tool to study activation of G-proteins in human neutrophils.
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